<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533585</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0818</org_study_id>
    <secondary_id>NCI-2012-01647</secondary_id>
    <nct_id>NCT00533585</nct_id>
  </id_info>
  <brief_title>BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and
      bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell
      lung cancer (NSCLC). The safety and effectiveness of this drug combination will also be
      studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sorafenib is designed to stop the growth of cells that are caused by genetic changes often
      associated with cancer. Paclitaxel is designed to work by blocking the mechanisms of cell
      division in cancer cells, which may cause them to die. Carboplatin is designed to work by
      interfering with the growth of cancer cells by stopping cell division. Bevacizumab is
      designed to prevent or slow down the growth of cancer cells by blocking the effects of a
      blood-vessel stimulating agent that plays an important role in the growth of both normal and
      abnormal blood vessels.

      If you are found to be eligible to take part in this study, you will receive 4 different
      drugs during the study. This study will follow a 3-week schedule known as a study &quot;cycle.&quot;

      In the first part of the study, researchers are trying to find out the highest dose of the
      study drugs that can be safely given together. The first group of 6 participants will receive
      lower doses of sorafenib and bevacizumab. The doses of paclitaxel and carboplatin will stay
      the same for up to 6 cycles for the study for all participants who complete 6 cycles. If the
      first 6 participants do not have intolerable side effects, the next group of patients will
      get higher doses of bevacizumab. The doses of sorafenib will be increased until at least some
      participants have unacceptable side effects. The dose that you get will not increase during
      the study, but if you have bad side effects, your dose of sorafenib, bevacizumab, paclitaxel,
      or carboplatin may be lowered at future visits.

      On Day 1 of each cycle, you will be given bevacizumab, paclitaxel, and carboplatin in your
      vein as an infusion. Paclitaxel will be infused over 3 hours, followed by carboplatin over 30
      minutes, followed by bevacizumab over 90 minutes for the first 2 cycles. Your bevacizumab
      infusion may be given over a shorter time period in later cycles. You will stay in the clinic
      for at least 30 minutes after your bevacizumab infusion for all cycles after 1 and 2. You
      will take sorafenib by mouth twice a day, once in the morning before 11:00 am and once in the
      evening before 11:00 p.m. Sorafenib should be taken with about 1 cup of water on an empty
      stomach (either 1 hour before a meal or 2 hours after a meal) or with a moderate fat diet
      (about 30% of calories from fat). Sorafenib must be swallowed whole without chewing.

      On Day 1 of Cycles 1 and 2, your complete medical history will be recorded, and you will have
      a physical exam including measurement of your vital signs and weight. You will be asked
      questions to find out how the disease is progressing and how the disease affects the quality
      of life. You will be asked about any side effects you may be experiencing. If possible, you
      should not change your medications between Cycle 1 Day 1 until all procedures are completed
      on Cycle 2 Day 3. Blood (about 5 teaspoons) and urine will be collected for routine tests.
      You will receive infusions of paclitaxel, carboplatin, and bevacizumab into a vein.

      On Cycle 1 Day 2, blood (about 1 tablespoon) will be drawn for routine tests.

      On Cycle 1 Day 3, blood (about 1 tablespoon) will be collected for routine tests. After your
      blood samples have been collected, you will be given your morning dose of sorafenib. You will
      be given sorafenib to take at home that night.

      On Cycle 2 Day 2, blood (about 1 tablespoon) will be drawn for routine tests. Once your blood
      samples has been collected, your morning dose of sorafenib will be given to you in the
      clinic. You will be given sorafenib to take at home that night.

      On Cycle 2 Day 3, blood (about 1 tablespoon) will be drawn for routine tests. Once your blood
      sample has been collected, your morning dose of sorafenib will be given to you in the clinic.
      Before you leave the clinic, you will be given enough sorafenib tablets to last until your
      next cycle visit.

      On Cycles 1-2 Days 8 and 15, your complete medical history will be recorded, and you will
      have a physical exam including measurement of your vital signs and weight. You will have a
      performance status evaluation. You will be asked about any side effects you may be
      experiencing. Blood (about 5 teaspoons) and urine will be collected for routine tests.

      On Day 1 of Cycle 3 and remaining cycles, you will return all study medication and/or the
      empty bottle. Your complete medical history will be recorded, and you will have a physical
      exam including measurement of your vital signs and weight. You will be asked questions to
      determine how the disease is progressing, and how the disease affects your quality of life.
      You will be asked about any side effects you may be experiencing. Blood (about 5 teaspoons)
      and urine will be collected for routine tests. You will receive infusions of paclitaxel,
      carboplatin, and bevacizumab. You will stay in the clinic for at least 30 minutes after your
      bevacizumab infusion. Before you leave the clinic, you will be given enough sorafenib to last
      until the next cycle.

      On Days 8 and 15 of Cycle 3 and remaining cycles, blood (about 5 teaspoons) and urine will be
      collected for routine tests.

      On Day 1 of all odd-numbered cycles (starting with Cycle 3, 5, 7, 9...), you will have CT
      scans, MRI scans, and/or other x-rays to check the status of the disease.

      Modified Dose Levels 4 and 5:

      To find out if interrupted dosing of sorafenib will result in fewer or less severe side
      effects, 2 additional dose levels, where the dose of sorafenib will be changed (modified),
      will be performed. For Modified Dose Level 4, sorafenib will be interrupted for 2 days after
      every 4-5 days . For Modified Dose Level 5, sorafenib will be interrupted for 1 week after 2
      weeks of continuous therapy.

      For these 2 additional dose levels, the sorafenib dosing schedule will be changed. There will
      be 6 patients enrolled at each dose level. Participants in Dose Level 4 may continue
      treatment for 4 to 6 cycles. This is done to accurately evaluate the dose level. Researchers
      will evaluate any side effects related to this new dosing schedule of sorafenib. After all 6
      patients have been enrolled in Dose level 4, then 6 additional patients will be enrolled in
      Dose Level 5. If no intolerable side effects are seen at Dose Level 5, then 6 additional
      patients can be enrolled in that dose level. This is done so additional PK testing can be
      done.

      For Modified Dose Level 4 and 5, &quot;on Day 1 of Cycle 1 and 2, you will be given bevacizumab,
      paclitaxel, and carboplatin in your vein as an infusion. Paclitaxel will be infused over 3
      hours, followed by carboplatin over 30 minutes, followed by bevacizumab over 90 minutes for
      the first 2 cycles. Your bevacizumab infusion may be given over a shorter time period in
      later cycles. You will stay in the clinic for at least 30 minutes after your bevacizumab
      infusion for all cycles after 1 and 2. &quot;

      Modified Dose level 4:

      For Modified Dose level 4, on Day 3 through Day 19 of Cycle 1, you will receive sorafenib by
      mouth in the morning, after the morning PK tests have been collected (on Day 3 only).
      Participants will take the evening dose of sorafenib on their own. After that, participants
      will take sorafenib on their own twice a day for 5 days on and 2 days off. This will continue
      through Day 19 on an outpatient basis.

      On Day 2 through Day 19 of Cycle 2, you will receive sorafenib by mouth in the morning, after
      the morning PK tests have been collected on Day 2 (Cycle 2 only). Participants will take the
      evening dose of sorafenib on their own. After that, participants will take sorafenib on their
      own twice a day for 5 days on and 2 days off. This will continue through Day 19 on an
      outpatient basis. The modified dose level 4 and 5 patients will not take sorafenib on Days 1,
      2, 6, 7, 13, 14, 20 and 21 of Cycle 1.

      Modified Dose level 5:

      For Modified Dose Level 5, on Day 3 through Day 15 of Cycle 1, you will receive sorafenib by
      mouth in the morning, after the morning PK tests have been collected (on Day 3 only).
      Participants will take the evening dose of sorafenib on their own. After that, participants
      will take sorafenib on their own twice a day for 14 days through Day 15 on an outpatient
      basis. Participants will not take sorafenib on Days 1, 2 and Days 16-21.

      On Day 2 through Day 15 of Cycle 2, you will receive sorafenib by mouth in the morning, after
      the morning PK tests have been collected (on Day 2 Cycle 2 only). Participants will take the
      evening dose of sorafenib on their own. After that, participants will take sorafenib on their
      own twice a day for 14 days through Day 15 on an outpatient basis.Participants will not take
      sorafenib on Days 1, 2 and Days 16-21.

      You may stay on study as long as the disease does not get worse, and intolerable side effects
      do not develop.

      Once you are off study, you will have an end-of-study visit 21-35 days after your last dose
      of the study drug. You will need to return all unused study medication and/or the empty
      bottles. You will have a physical exam, including measurement of your vital signs, height,
      and weight. You will have a performance status evaluation and an ECG. You will be asked about
      any side effects you may be experiencing. CT scans, MRIs, and/or x-rays will be taken to
      check the status of the disease. Blood (about 5 teaspoons) and urine will be collected for
      routine blood tests. Women who are able to have children must have a negative blood (about
      1-2 teaspoons ) pregnancy test.

      This is an investigational study. Sorafenib, paclitaxel, carboplatin, and bevacizumab are all
      FDA approved and commercially available. The combination of these 4 drugs is not FDA
      approved, and it has been authorized for use in research only. Up to 60 patients will take
      part in this multicenter study. Up to 30 patients will be enrolled at M.D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of BAY 43-9006 (sorafenib) and Bevacizumab in Combination with Carboplatin and Paclitaxel</measure>
    <time_frame>First day of every 21 day cycle</time_frame>
    <description>If a dose limiting toxicity (DLT) occurs in â‰¥ 2 out of 6 patients at dose levels 2 - 6, dose escalation will be stopped and that dose will be declared the toxic dose. The dose level below will be declared the maximum tolerated dose if at this dose level 6 patients can be treated such that no more than 1 patient experiences a DLT.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>BAY 43-9006 + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY 43-9006 (Sorafenib) + Bevacizumab + Paclitaxel + Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 43-9006</intervention_name>
    <description>Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.</description>
    <arm_group_label>BAY 43-9006 + Bevacizumab</arm_group_label>
    <other_name>Sorafenib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>200 mg/m^2 By Vein Over 3 Hours on Day 1.</description>
    <arm_group_label>BAY 43-9006 + Bevacizumab</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.</description>
    <arm_group_label>BAY 43-9006 + Bevacizumab</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.</description>
    <arm_group_label>BAY 43-9006 + Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and the willingness to sign a written informed consent. A signed
             informed consent must be obtained prior to any study specific procedures.

          2. Patients must have Stage IIIB (with malignant pleural effusions) or Stage IV
             histological or cytological confirmation of non-small cell carcinoma (excluding
             squamous).

          3. Age &gt;/= 18 years old

          4. Patients must have at least 1 measurable lesion. Lesions must be evaluated by computed
             tomography (CT) scan or magnetic resonance imagining (MRI)

          5. Eastern Cooperative Oncology (ECOG) Performance Status of 0 - 1

          6. Controlled blood pressure (defined as systolic BP &lt;/= 150mmHg and diastolic &lt;/= 90
             mmHg)

          7. Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to start of first dose: Hemoglobin
             &gt;/= 9.0 g/dL; White blood cell (WBC) count &gt;/= 2,500/mm3, Absolute neutrophil count
             (ANC) &gt;/= 1,500/mm3, Platelet count &gt;/= 100,000/mm3, Total bilirubin &lt;/= 1.5 times the
             upper limit of normal (ULN), ALT and AST &lt;/= 2.5 x ULN (&lt;/=5 x ULN for patients with
             liver involvement), international normalized ratio (INR) &lt;/= 1.5 and activated partial
             thromboplastin time (aPTT) within normal limits.

          8. Inclusion Criteria #7: Serum creatinine &lt;/= ULN or creatinine clearance (CrCl) &gt;/= 45
             mL/min (CrCl = Wt (kg) x (140 - age)/72 x Cr level, female x 0.85) for patients with
             creatinine levels above institutional normal. Urinalysis (UA) must show less than 1+
             protein urine, or the patient will require a repeat UA. If repeat UA shows 1+ protein
             or more, a 24 hour collection will be required and must show total protein &lt;/= 1000
             mg/24 hour to be eligible

          9. Women of childbearing potential must have a negative serum pregnancy test performed
             within 7 days prior to start of treatment.

         10. Women of childbearing potential and men must agree to use adequate contraception prior
             to study entry and for the duration of study participation, including the 30 day
             period after last study drug dosing. The investigator should advise the patient what
             is considered adequate contraception.

        Exclusion Criteria:

          1. Patients with squamous histology.

          2. Cardiac disease: Congestive heart failure (CHF) &gt; Class II New York Heart Association
             (NYHA); active coronary artery disease (myocardial infarction) [MI] more than 6 months
             prior to study entry is allowed); or serious cardiac ventricular arrhythmias requiring
             anti-arrhythmic therapy (beta-blockers or digoxin are permitted)

          3. Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic
             pressure &gt; 90 mmHg despite optimal medical management

          4. Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or C

          5. Active clinically serious infections (&gt; Grade 2 NCI-CTC Version 3.0)

          6. History of brain metastases. Patients with history of brain metastases are eligible as
             long as the metastasis has been treated with either stereotactic whole brain radiation
             or neurosurgery, patient does not require ongoing treatment with dexamethasone and
             patient's radiographic imaging is stable &gt;/= 4 weeks from start of treatment. Time
             from brain metastasis treatment to first study treatment must meet the following
             criteria: Stereotactic whole brain radiation &gt;/= 4 weeks from first study treatment,
             Neurosurgery &gt;/= 24 weeks from first study treatment, continued in exclusion # 7

          7. Continued from exclusion criterion # 6: Brain biopsy &gt;/= 12 weeks from first study
             treatment.

          8. Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic
             drugs (phenytoin, carbamazepine or phenobarbital) is not allowed

          9. Thrombotic or embolic events such as cerebrovascular accident, transient ischemic
             attacks, deep vein thrombosis or pulmonary embolism

         10. Organ allograft

         11. Evidence or history of bleeding diathesis or coagulopathy

         12. History of/or current evidence of hemoptysis (bright red blood of 1/2 teaspoon or
             more)

         13. Peripheral neuropathy &gt;/= Grade 2

         14. Anticancer chemotherapy or immunotherapy: Anticancer therapy is defined as any agent
             or combination of agents with clinically proven anticancer activity administered by
             any route with the purpose of affecting the cancer, either directly or indirectly,
             including palliative and therapeutic endpoints (except patients who have received
             adjuvant chemotherapy &gt; 52 weeks from Cycle 1 Day 1)

         15. Radiotherapy to the target lesions within 3 weeks of start of first dose. Toxicities
             from radiotherapy must have resolved prior to start of first dose.

         16. No major surgery, open biopsy or significant traumatic injury within 4 weeks of start
             of first dose

         17. Serious, non-healing wound, ulcer, or bone fracture

         18. Granulocyte growth factors (G-CSF), within 3 weeks of study entry.

         19. Patients taking chronic erythropoietin are permitted provided no dose adjustment is
             made within 2 months prior to start of first dose

         20. Pregnant or breast feeding patients

         21. Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

         22. Known or suspected allergy to any recombinant human antibodies, or compounds of
             similar chemical or biologic composition to sorafenib or any of the drugs in this
             study

         23. Any condition that is unstable or could jeopardize the safety or compliance of the
             patient in the study

         24. Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in the study EXCEPT cervical cancer in situ, treated basal cell
             carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively
             treated &gt; 3 years prior to study entry

         25. Any condition that impairs the patient's ability to swallow pills as a whole

         26. Any malabsorption conditions

         27. Therapeutic anticoagulation with warfarin, heparins, or heparinoids

         28. Patients takin phenytoin, carbamazepine, and Phenobarbital

         29. Patients taking rifampin, St. John's Wort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Blumenschein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>malignant pleural effusions</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Taxol</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paraplatin</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>BAY 43-9006</keyword>
  <keyword>Anti-VEGF monoclonal antibody</keyword>
  <keyword>rhuMAb-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

